Arena Pharmaceuticals (ARNA) slides 7.8% and adds to a 6.5% loss on Friday after the EU's CHMP...

Arena Pharmaceuticals (ARNA) slides 7.8% and adds to a 6.5% loss on Friday after the EU's CHMP health regulator didn't make a decision about approving the company's Belviq weight-loss treatment at meetings last week, meaning the firm will have to wait for at least another month for a ruling. It doesn't help that Arena received a 180-day list of questions about Belviq. "It's not pretty," says Adam Feuerstein. (Arena 8-K)

From other sites
Comments (3)
  • New Superhuman
    , contributor
    Comments (1180) | Send Message
    Why does Adam Feuerstein always feel the need to step on ARNA? What's his agenda?
    22 Jan 2013, 10:24 AM Reply Like
    , contributor
    Comment (1) | Send Message
    Probably because he felt that Belviq would never get approved by the FDA and he was wrong, and his fragile ego was damaged that's why he can't write anything favorable about Arena.
    22 Jan 2013, 12:40 PM Reply Like
  • User 393631
    , contributor
    Comment (1) | Send Message
    Feuerstein and all other commentators are usually amused by the effects their comments have not their validity. For instance please explain "180-day list" and "It's not pretty". Both purely designed to raise doubt without an explanation of these remarks. My wife is holding a script for Belviq since October the doctor would not recommend Qysimia due to her HBP.
    22 Jan 2013, 12:42 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs